Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.

Cyclosporine A (CsA) inhibits P-glycoprotein (Pgp)-mediated cellular export of anthracyclines at clinically achievable concentrations. This randomized controlled trial was performed to test the benefit of CsA addition to treatment with cytarabine and daunorubicin (DNR) in patients with poor-risk acute myeloid leukemia (AML). A total of 226 patients were randomly assigned to sequential treatment with cytarabine and infusional DNR with or without intravenous CsA. Remitting patients received one course of consolidation chemotherapy that included DNR with or without CsA as assigned during induction. Addition of CsA significantly reduced the frequency of resistance to induction chemotherapy (31% versus 47%, P =.0077). Whereas the rate of complete remission was not significantly improved (39% versus 33%, P =.14), relapse-free survival (34% versus 9% at 2 years, P =.031) and overall survival (22% versus 12%, P =.046) were significantly increased with CsA. The effect of CsA on survival was greatest in patients with moderate or bright Pgp expression (median 12 months with CsA versus 4 months for controls) compared to patients with absent or low Pgp expression (median 6 months in both arms). The frequency of induction deaths was 15% with CsA and 18% in controls. Steady-state serum concentrations of DNR (P =.0089) and daunorubicinol (P <.0001) were significantly higher in CsA-treated patients. Survival (P =.0003) and induction response (P =.028) improved with increasing DNR concentration in CsA-treated patients but not in controls, suggesting a targeted interaction by CsA to enhance anthracycline cytotoxicity. These results indicate that addition of CsA to an induction and consolidation regimen containing infusional DNR significantly reduces resistance to DNR, prolongs the duration of remission, and improves overall survival in patients with poor-risk AML.

[1]  P. Workman,et al.  Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A. , 1989, Biochemical pharmacology.

[2]  W. Dalton,et al.  Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  T. Grogan,et al.  Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML). , 1996, Leukemia research.

[4]  A. Tomida,et al.  Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance. , 1993, Journal of the National Cancer Institute.

[5]  M. Slovak,et al.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study , 2000 .

[6]  R. L. Felsted,et al.  P-glycoprotein-independent mechanism of resistance to VP-16 in multidrug-resistant tumor cell lines: pharmacokinetic and photoaffinity labeling studies. , 1990, Molecular pharmacology.

[7]  T. Tsuruo,et al.  Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. , 1992, Blood.

[8]  M. Boiocchi,et al.  Increased chemosensitivity to doxorubicin of intrinsically multidrug-resistant human colon carcinoma cells by prolonged exposure to verapamil. , 1993, European journal of cancer.

[9]  D. Ross,et al.  Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporin A and cremophor EL. , 1994, Blood.

[10]  S. Murray,et al.  Enhancement by cyclosporin A of daunorubicin efficacy in Ehrlich ascites carcinoma and murine hepatoma 129. , 1987, Cancer research.

[11]  O. Haas,et al.  MDR1 gene expression and treatment outcome in acute myeloid leukemia. , 1991, Journal of the National Cancer Institute.

[12]  F. Appelbaum,et al.  Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases. , 1995, Blood.

[13]  T. Grogan,et al.  Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  F. Behm,et al.  Cyclosporin A induces apoptosis in childhood acute lymphoblastic leukemia cells. , 1998, Blood.

[15]  B. Sikic,et al.  Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  C. Tangen,et al.  A Southwest Oncology Group study , 1993 .

[17]  C. Cass,et al.  Effect of duration of exposure to verapamil on vincristine activity against multidrug-resistant human leukemic cell lines. , 1989, Cancer research.

[18]  G. M. Wilson,et al.  Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. , 1994, Cancer research.

[19]  Iscn International System for Human Cytogenetic Nomenclature , 1978 .

[20]  I. Pastan,et al.  Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[21]  S. Bates,et al.  P‐glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines , 1991, International journal of cancer.

[22]  G. Marit,et al.  Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. , 1995, Leukemia.

[23]  S. Pocock,et al.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.

[24]  T. Grogan,et al.  Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. , 2001, Blood.

[25]  M. Slovak,et al.  Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.

[26]  S. Gupta,et al.  Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. , 1986, The Journal of clinical investigation.

[27]  D.,et al.  Regression Models and Life-Tables , 2022 .

[28]  R. Beuscart,et al.  Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases , 1989, British journal of haematology.

[29]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[30]  B. Sikic,et al.  Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Michelson,et al.  Drug resistance-reversal strategies: comparison of experimental data with model predictions. , 1991, Journal of the National Cancer Institute.

[32]  E. Solary,et al.  Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. , 1996, Blood.

[33]  V. Ling,et al.  Identification of members of the P-glycoprotein multigene family , 1989, Molecular and cellular biology.

[34]  J. Ordonez,et al.  Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. , 1993, Blood.

[35]  E. Estey,et al.  Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. , 1999, Blood.

[36]  A. List,et al.  Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. , 1996, Leukemia.

[37]  David R. Cox The analysis of binary data , 1970 .

[38]  A. Fojo,et al.  Expression of a 95 kDa membrane protein is associated with low daunorubicin accumulation in leukaemic blast cells. , 1995, British Journal of Cancer.

[39]  M. Sehested,et al.  Relationship of VP-16 to the Classical Multidrug Resistance Phenotype1 , 2006 .

[40]  H. Garewal,et al.  Expression of the multidrug resistance gene product (P‐glycoprotein) in myelodysplasia is associated with a stem cell phenotype , 1991, British journal of haematology.

[41]  S. Ergün,et al.  Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. , 1997, Blood.

[42]  L. Doyle,et al.  A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Endicott,et al.  Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance , 1986, Nature.

[44]  T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[45]  K. Brouwer,et al.  Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver. , 1998, Cancer research.

[46]  M. Slovak,et al.  Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.

[47]  C. Bloomfield,et al.  Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  E. Estey,et al.  Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  D. Ribatti,et al.  Antiangiogenesis by cyclosporine. , 1998, Experimental hematology.

[50]  I. T. Young Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources. , 1977, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[51]  P. Sonneveld,et al.  Overexpression of the MDRL gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin‐A , 1990, International journal of cancer.